In 2023, the FDA approved the first cell-based gene therapies to treat sickle cell disease, a lifelong illness that shaves 20–25 years off average life expectancy. However, the process of collecting and genetically modifying a patient’s own blood cells is intensive, with treatments costing as much as $3.3 million. Despite

For decades, the Science Center has worked alongside founders and investors at some of the most consequential moments in a company’s trajectory — when science is translating into a product, and when capital decisions determine whether that progress accelerates or stalls. Over time, patterns became clear.

There is no innovation shortage in healthcare. There are countless founders who are deeply committed to improving the standard of care; yet, many clinically sound innovations never get to the finish line. They stall. They can pilot it, but they can’t scale. They can generate enthusiasm, but fail to achieve

This report synthesizes the longitudinal reflections of Sajida, a current sophomore at Drexel University and STEM major, regarding her participation in the FirstHand™ program. Her testimony provides a powerful look at how FirstHand helped shape her academic trajectory and personal identity over a decade. While this case study centers